CME/CE

Use the tool below to view all available Prova Series

CME/CE In-Person & Virtual Event
The CELMoD Shift: Translating Protein Degradation Science Into Practice-Changing Myeloma Care
December 11, 2026
New Orleans, Louisiana
1.50 credits
MinuteCE®
Beyond Checkpoint Blockade in SCLC: Emerging Antigen Targets and Treatment Strategies Across Disease Stages
Neal Ready, MD, PhD; Ticiana Leal, MD
0.50 credits 4 episodes
- Neal Ready, MD, PhD
- Ticiana Leal, MD
0.50 credits 4 episodes
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
CME/CE Broadcast Replay
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
Maria Fleseriu, MD, FACE; Beverly MK Biller, MD, FACP
1.50 credits
- Maria Fleseriu, MD, FACE
- Beverly MK Biller, MD, FACP
- Mark Gurnell, MD
1.50 credits
CME/CE Virtual Event
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
Multiple dates available
1.00 credit
From Data to Decision: Patient Selection and Real-World Application
From Data to Decision: Patient Selection and Real-World Application
MinuteCE®
From Data to Decision: Patient Selection and Real-World Application
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 program credits
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 program credits
Building the Team: Integrating Immunotherapy Into Multidisciplinary Care
Building the Team: Integrating Immunotherapy Into Multidisciplinary Care
MinuteCE®
Building the Team: Integrating Immunotherapy Into Multidisciplinary Care
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 program credits
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 program credits
NEW EPISODE
Precision in Practice—Bringing Targeted Therapy to mHSPC
Precision in Practice—Bringing Targeted Therapy to mHSPC
MinuteCE®
Precision in Practice—Bringing Targeted Therapy to mHSPC
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
NEW EPISODE
The Power of Timing: Therapies That Change Outcomes
The Power of Timing: Therapies That Change Outcomes
MinuteCE®
The Power of Timing: Therapies That Change Outcomes
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
NEW EPISODE
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
MinuteCE®
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
MinuteCE®
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Tiffany Traina, MD; Javier Cortes, MD, PhD
0.75 program credits
- Tiffany Traina, MD
- Javier Cortes, MD, PhD
0.75 program credits
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
MinuteCE®
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Javier Cortes, MD, PhD
0.75 program credits
- Javier Cortes, MD, PhD
0.75 program credits
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
MinuteCE®
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Javier Cortes, MD, PhD
0.75 program credits
- Javier Cortes, MD, PhD
0.75 program credits
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
MinuteCE®
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
Tiffany Traina, MD; Javier Cortes, MD, PhD
0.75 program credits
- Tiffany Traina, MD
- Javier Cortes, MD, PhD
0.75 program credits
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
CME/CE
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
Susana Campos, MD, MPH; Robert Coleman, MD, FACOG
1.00 credit
- Susana Campos, MD, MPH
- Robert Coleman, MD, FACOG
- Debra Richardson, MD
1.00 credit
Cracking the Code in Localized, nmCSPC: Risk, Treatment, and Timing
Cracking the Code in Localized, nmCSPC: Risk, Treatment, and Timing
CME/CE
Cracking the Code in Localized, nmCSPC: Risk, Treatment, and Timing
Neeraj Agarwal, MD, FASCO; Rana McKay, MD
0.25 credits
- Neeraj Agarwal, MD, FASCO
- Rana McKay, MD
0.25 credits
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
CME/CE
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
Neeraj Agarwal, MD, FASCO; Rana McKay, MD
0.25 credits
- Neeraj Agarwal, MD, FASCO
- Rana McKay, MD
0.25 credits

CME/CE

Popular

Title